San Francisco, California – Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs, announced a $52 million Series A financing. The round was led by Insight Partners and included investments from Dolby Family Ventures, Upfront Ventures, BOLD Capital Partners, Eli Lilly & Company, Digitalis Ventures, FreeFlow Ventures, and UCB Ventures.

Switch Therapeutics is co-founded by Dee Datta and is based in San Francisco, California. The company’s mission is to develop treatments for diseases affecting the central nervous system and systemic indications with significant unmet needs. To achieve this goal, Switch has developed a novel gene knockdown approach based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard, and City of Hope called CASi (Conditionally Activated siRNAs). This proprietary platform combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell-selective RNAi activity.

“We are very excited about our Series A funding as it will enable us to further advance our lead development program into clinical studies as well as expand our pipeline into additional disease areas where we can make a meaningful difference in patient outcomes.,” said Dee Datta Co-Founder at Switch Therapeutics.